

# Andrew H Evans

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/248637/publications.pdf>

Version: 2024-02-01

89  
papers

4,765  
citations

136950

32  
h-index

98798

67  
g-index

90  
all docs

90  
docs citations

90  
times ranked

4153  
citing authors

#	ARTICLE	IF	CITATIONS
1	Punding in Parkinson's disease: Its relation to the dopamine dysregulation syndrome. <i>Movement Disorders</i> , 2004, 19, 397-405.	3.9	488
2	Compulsive drug use linked to sensitized ventral striatal dopamine transmission. <i>Annals of Neurology</i> , 2006, 59, 852-858.	5.3	435
3	Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours. <i>Brain</i> , 2011, 134, 969-978.	7.6	283
4	Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry?. <i>Lancet Neurology</i> , The, 2003, 2, 595-604.	10.2	278
5	Clinical spectrum of impulse control disorders in Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 121-127.	3.9	264
6	Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: A prospective study using single-dose challenges. <i>Movement Disorders</i> , 2005, 20, 151-157.	3.9	262
7	Pathological gambling in Parkinson's disease: Risk factors and differences from dopamine dysregulation. An analysis of published case series. <i>Movement Disorders</i> , 2007, 22, 1757-1763.	3.9	246
8	Dopamine dysregulation syndrome in Parkinson's disease. <i>Current Opinion in Neurology</i> , 2004, 17, 393-398.	3.6	218
9	Impulsive and compulsive behaviors in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 1561-1570.	3.9	192
10	Active surveillance for the management of localized prostate cancer: Guideline recommendations. <i>Canadian Urological Association Journal</i> , 2015, 9, 171.	0.6	184
11	Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease – Clinical practice recommendations. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1023-1030.	2.2	126
12	Parkinson's disease in the Western Pacific Region. <i>Lancet Neurology</i> , The, 2019, 18, 865-879.	10.2	116
13	Impulse Control and Related Disorders in Parkinson's Disease. <i>Annals of the New York Academy of Sciences</i> , 2008, 1142, 85-107.	3.8	109
14	Do dyskinesia and pain share common pathophysiological mechanisms in Parkinson's disease?. <i>Movement Disorders</i> , 2008, 23, 1689-1695.	3.9	85
15	What speech can tell us: A systematic review of dysarthria characteristics in Multiple Sclerosis. <i>Autoimmunity Reviews</i> , 2018, 17, 1202-1209.	5.8	79
16	Punding and dyskinesias. <i>Movement Disorders</i> , 2006, 21, 2214-2217.	3.9	76
17	Dopamine agonist-induced pathological gambling in restless legs syndrome due to multiple sclerosis. <i>Movement Disorders</i> , 2007, 22, 590-591.	3.9	68
18	Recognition of a dopamine replacement therapy dependence syndrome in Parkinson's disease: a pilot study. <i>Supplementary. Drug and Alcohol Dependence</i> , 2004, 76, 305-310.	3.2	58

#	ARTICLE	IF	CITATIONS
19	The anteromedial GPI as a new target for deep brain stimulation in obsessive compulsive disorder. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 815-821.	1.5	52
20	Excessive hoarding in Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 1026-1033.	3.9	50
21	Parkinsonism as a Third Wave of the COVID-19 Pandemic?. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1343-1353.	2.8	50
22	Scales to assess impulsive and compulsive behaviors in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2019, 34, 791-798.	3.9	49
23	Compulsive use of dopaminergic drug therapy in Parkinson's disease: Reward and anti-reward. <i>Movement Disorders</i> , 2010, 25, 867-876.	3.9	48
24	Objective measurement in routine care of people with Parkinson's disease improves outcomes. <i>Npj Parkinson's Disease</i> , 2018, 4, 10.	5.3	45
25	Canadian guidelines for the management of the small renal mass (SRM). <i>Canadian Urological Association Journal</i> , 2015, 9, 160.	0.6	45
26	Growth kinetics of small renal masses: A prospective analysis from the Renal Cell Carcinoma Consortium of Canada. <i>Canadian Urological Association Journal</i> , 2014, 8, 24.	0.6	44
27	Validation of a Smartphone Application Measuring Motor Function in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2016, 6, 371-382.	2.8	44
28	Integrating Patient Concerns into Parkinson's Disease Management. <i>Current Neurology and Neuroscience Reports</i> , 2017, 17, 3.	4.2	44
29	Immortalized Parkinson's Disease lymphocytes have enhanced mitochondrial respiratory activity. <i>DMM Disease Models and Mechanisms</i> , 2016, 9, 1295-1305.	2.4	40
30	A pilot study of the utility of cerebrospinal fluid neurofilament light chain in differentiating neurodegenerative from psychiatric disorders: A C-reactive protein for psychiatrists and neurologists?. <i>Australian and New Zealand Journal of Psychiatry</i> , 2020, 54, 57-67.	2.3	40
31	Novel Approach to Stem Cell Therapy in Parkinson's Disease. <i>Stem Cells and Development</i> , 2018, 27, 951-957.	2.1	39
32	Time to diagnosis in younger-onset dementia and the impact of a specialist diagnostic service. <i>International Psychogeriatrics</i> , 2022, 34, 367-375.	1.0	38
33	Directional Deep Brain Stimulation for Parkinson's Disease: Results of an International Crossover Study With Randomized, Double-Blind Primary Endpoint. <i>Neuromodulation</i> , 2022, 25, 817-828.	0.8	34
34	Impulsive-compulsive spectrum behaviors in pathologically confirmed progressive supranuclear palsy. <i>Movement Disorders</i> , 2010, 25, 638-642.	3.9	33
35	The efficacy of apomorphine – A non-motor perspective. <i>Parkinsonism and Related Disorders</i> , 2016, 33, S28-S35.	2.2	30
36	Pain sensitivity in Parkinson's disease: Systematic review and meta-analysis. <i>Parkinsonism and Related Disorders</i> , 2018, 48, 17-27.	2.2	30

#	ARTICLE	IF	CITATIONS
37	The relationship between specific cognitive defects and burden of care in Parkinson's disease. <i>International Psychogeriatrics</i> , 2016, 28, 275-281.	1.0	27
38	The morbidity related to atrial fibrillation at a tertiary centre in one year: 9.0% of all strokes are potentially preventable. <i>Journal of Clinical Neuroscience</i> , 2002, 9, 268-272.	1.5	26
39	Deep brain stimulation for severe treatment-resistant obsessive-compulsive disorder: An open-label case series. <i>Australian and New Zealand Journal of Psychiatry</i> , 2018, 52, 699-708.	2.3	25
40	Punding in patients on dopamine agonists for restless leg syndrome. <i>Movement Disorders</i> , 2009, 24, 140-141.	3.9	24
41	Tremor in multiple sclerosis is associated with cerebello-thalamic pathology. <i>Journal of Neural Transmission</i> , 2017, 124, 1509-1514.	2.8	24
42	L-dopa-responsive Parkinson's syndrome in association with phenylketonuria: In vivo dopamine transporter and D2 receptor findings. <i>Movement Disorders</i> , 2004, 19, 1232-1236.	3.9	23
43	Acoustic Speech Analytics Are Predictive of Cerebellar Dysfunction in Multiple Sclerosis. <i>Cerebellum</i> , 2020, 19, 691-700.	2.5	22
44	Topiramate for Abnormal Eating Behaviour in Frontotemporal Dementia. <i>Behavioural Neurology</i> , 2013, 27, 285-286.	2.1	21
45	Parkinson disease: A systemic review of pain sensitivities and its association with clinical pain and response to dopaminergic stimulation. <i>Journal of the Neurological Sciences</i> , 2018, 395, 172-206.	0.6	20
46	A 10 year retrospective cohort study of inpatients with younger-onset dementia. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 294-301.	2.7	15
47	A Conditioned Response as a Measure of Impulsive-Compulsive Behaviours in Parkinson's Disease. <i>PLoS ONE</i> , 2014, 9, e89319.	2.5	15
48	Dyskinetic patients show rebound worsening of affect after an acute L-dopa challenge. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 514-519.	2.2	14
49	Practical approaches to commencing device-assisted therapies for Parkinson disease in Australia. <i>Internal Medicine Journal</i> , 2017, 47, 1107-1113.	0.8	14
50	The Diagnostic Challenge of Young-Onset Dementia Syndromes and Primary Psychiatric Diseases: Results From a Retrospective 20-Year Cross-Sectional Study. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2022, 34, 44-52.	1.8	13
51	Neurocognitive correlates of medication-induced addictive behaviours in Parkinson's disease: A systematic review. <i>European Neuropsychopharmacology</i> , 2018, 28, 561-578.	0.7	10
52	Functional neuroplasticity in response to cerebello-thalamic injury underpins the clinical presentation of tremor in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020, 26, 696-705.	3.0	10
53	Objective Measurement and Characterization of Sleep Benefit in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 590-596.	1.5	9
54	Mortality in dementia is predicted by older age of onset and cognitive presentation. <i>Australian and New Zealand Journal of Psychiatry</i> , 2021, , 000486742110410.	2.3	9

#	ARTICLE	IF	CITATIONS
55	Dopamine agonist-induced substance addiction: The next piece of the puzzle. <i>Journal of Clinical Neuroscience</i> , 2011, 18, 191-192.	1.5	8
56	Neuropsychiatric manifestations of Parkinson's disease. <i>Australasian Psychiatry</i> , 2016, 24, 529-533.	0.7	8
57	Validation of a precision tremor measurement system for multiple sclerosis. <i>Journal of Neuroscience Methods</i> , 2019, 311, 377-384.	2.5	8
58	Latent Autoimmune Diabetes in Stiff-Person Syndrome. <i>Diabetes Care</i> , 2014, 37, e214-e215.	8.6	7
59	Novel Functional MRI Task for Studying the Neural Correlates of Upper Limb Tremor. <i>Frontiers in Neurology</i> , 2018, 9, 513.	2.4	7
60	Tractography-Guided Deep Brain Stimulation of the Anteromedial Globus Pallidus Internus for Refractory Obsessive-Compulsive Disorder: Case Report. <i>Neurosurgery</i> , 2020, 86, E558-E563.	1.1	7
61	Establishing apomorphine treatment in Thailand: understanding the challenges and opportunities of Parkinson's disease management in developing countries. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 523-537.	2.8	7
62	Regular Transition Zone Biopsy during Active Surveillance for Prostate Cancer May Improve Detection of Pathological Progression. <i>Journal of Urology</i> , 2014, 192, 1088-1093.	0.4	6
63	Subjective perception of sleep benefit in Parkinson's disease: Valid or irrelevant?. <i>Parkinsonism and Related Disorders</i> , 2017, 42, 90-94.	2.2	6
64	Pain and dyskinesia in Parkinson's disease may share common pathophysiological mechanisms – An fMRI study. <i>Journal of the Neurological Sciences</i> , 2020, 416, 116905.	0.6	6
65	Feasibility of Smartphone-Based Testing of Interference in Parkinson's Disease. <i>Neurodegenerative Diseases</i> , 2018, 18, 133-142.	1.4	5
66	Anti-Ma2-associated paraneoplastic encephalitis eat, sleep and repeat. <i>Internal Medicine Journal</i> , 2019, 49, 931-932.	0.8	5
67	A guide to management of neuropsychiatric manifestations of Parkinson's disease. <i>Australasian Psychiatry</i> , 2016, 24, 534-537.	0.7	4
68	OCD symptoms in succinic semialdehyde dehydrogenase (SSADH) deficiency: a case report. <i>BMC Psychiatry</i> , 2020, 20, 395.	2.6	4
69	Characteristics of advanced Parkinson's disease patients seen in movement disorder clinics - Australian results from the cross-sectional OBSERVE study. <i>Clinical Parkinsonism &amp; Related Disorders</i> , 2021, 4, 100075.	0.9	4
70	Sodium selenate as a disease-modifying treatment for progressive supranuclear palsy: protocol for a phase 2, randomised, double-blind, placebo-controlled trial. <i>BMJ Open</i> , 2021, 11, e055019.	1.9	4
71	Neuropsychiatric symptoms as the presenting feature of acquired hepatocerebral degeneration. <i>Australian and New Zealand Journal of Psychiatry</i> , 2014, 48, 959-960.	2.3	3
72	Cerebrospinal fluid cannot be used to distinguish inflammatory myelitis from congestive myelopathy due to spinal dural arteriovenous fistula: case series. <i>BMJ Neurology Open</i> , 2019, 1, e000019.	1.6	3

#	ARTICLE	IF	CITATIONS
73	OnabotulinumtoxinA treatment for MS-tremor modifies fMRI tremor response in central sensory-motor integration areas. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 40, 101984.	2.0	3
74	Oromandibular parafunction in chronic graft-versus-host disease: novel association and treatment approach. <i>Internal Medicine Journal</i> , 2021, 51, 1950-1953.	0.8	3
75	Evaluation of Nonmotor Symptoms in Diagnosis of Parkinsonism and Tremor. <i>Parkinson's Disease</i> , 2016, 2016, 1-6.	1.1	2
76	Treatment advances in Parkinson disease: Same script different cast?. <i>Journal of Clinical Neuroscience</i> , 2018, 47, 354-355.	1.5	2
77	A retrospective review of MRI features associated with metastasis-free survival in women with breast cancer: focusing on skin thickening and skin enhancement. <i>British Journal of Radiology</i> , 2021, 94, 20210472.	2.2	2
78	Autoimmune Encephalitis in Long-Standing Schizophrenia: A Case Report. <i>Frontiers in Neurology</i> , 2021, 12, 810926.	2.4	2
79	Progressive parkinsonism, oculomotor abnormalities and autonomic dysfunction: Clinicopathological case. <i>Movement Disorders</i> , 2011, 26, 424-429.	3.9	1
80	Skin Picking Heraldng Parkinson's Disease. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2016, 28, e23-e24.	1.8	1
81	Neurofilament light chain in psychiatric and neurodegenerative disorders: A reactive protein for the brain?. <i>Alzheimer's and Dementia</i> , 2020, 16, e041347.	0.8	1
82	Cerebrospinal fluid Alzheimer disease biomarkers for assessing cognitive and neuropsychiatric symptoms: Expanding the toolkit in the psychiatrist's diagnostic armamentarium. <i>Australian and New Zealand Journal of Psychiatry</i> , 2022, 56, 865-866.	2.3	1
83	026...Characteristics of advanced parkinson's disease patients seen in movement disorder clinics - australian results from the cross-sectional observe study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, A11.1-A11.	1.9	0
84	Brief Psychiatric Screening Questionnaire in Parkinson's Disease. <i>Parkinson's Disease</i> , 2019, 2019, 1-5.	1.1	0
85	Type 1 cryoglobulinemic neuropathy associated with lymphoplasmacytic lymphoma. <i>Acta Neurologica Belgica</i> , 2021, 121, 1887-1890.	1.1	0
86	BeYOND: Biomarkers in younger-onset neurocognitive disorders - The first 50 participants. <i>Alzheimer's and Dementia</i> , 2020, 16, e040714.	0.8	0
87	Sniffin' Sticks Screening 12 Test can assist in the clinical distinction between psychiatric disorders and neurological/neurodegenerative disorders. <i>Alzheimer's and Dementia</i> , 2020, 16, e042482.	0.8	0
88	Mortality in FTD: An Australian perspective. <i>Alzheimer's and Dementia</i> , 2021, 17, e058561.	0.8	0
89	The diagnostic challenge among young onset dementia syndromes and primary psychiatric diseases: Results of a retrospective, 20-year cross-sectional study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0